NCT03639987: A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
- State
- Stopped early
- Phase
- Phase 2
- People
- 52 taking part
- Started
- 20 Dec 2018
- Primary completion
- 30 Jul 2019
- Arms
- Group 2
- Results
- Posted on the registry
- 21 Aug 2018: Trial registered
- 20 Dec 2018: Trial started
- 30 Jul 2019: Trial terminated
- 16 Sep 2021: Trial results posted